Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer

Background:  High‐intensity focused ultrasound (HIFU) is a minimally invasive technique used in achieve coagulation necrosis. We evaluated biochemical disease‐free survival rates, predictors of clinical outcome and morbidity in patients with localized prostate cancer treated with HIFU. Methods:  A t...

Full description

Saved in:
Bibliographic Details
Published in:International journal of urology 2006-03, Vol.13 (3), p.228-233
Main Authors: UCHIDA, TOYOAKI, OHKUSA, HIROSHI, YAMASHITA, HIDEYUKI, SHOJI, SUNAO, NAGATA, YOSHIHIRO, HYODO, TORU, SATOH, TAKEFUMI
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Disease-Free Survival
Endosonography
Equipment Design
Follow-Up Studies
high-intensity focused ultrasound
Humans
Male
Middle Aged
minimally invasive therapy
prostate cancer
prostate-specific antigen
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - therapy
Rectum
Time Factors
Treatment Outcome
Ultrasonic Therapy - instrumentation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background:  High‐intensity focused ultrasound (HIFU) is a minimally invasive technique used in achieve coagulation necrosis. We evaluated biochemical disease‐free survival rates, predictors of clinical outcome and morbidity in patients with localized prostate cancer treated with HIFU. Methods:  A total of 181 consecutive patients underwent HIFU with the use of Sonablate (Focus Surgery, Indianapolis, IN, USA). Biochemical recurrence was defined according to the criteria recommended by the American Society for Therapeutic Radiology and Oncology Consensus Panel. The median age and pretreatment prostate‐specific antigen (PSA) level were 70 years (range 44–88) and 9.76 ng/mL (range 3.39–89.60). A total of 95 patients (52%) were treated with neoadjuvant hormones. The median follow‐up period for all patients was 18.0 months (range 4–68). Results:  The biochemical disease‐free survival rates at 1, 3 and 5 years in all patients were 84%, 80% and 78%, respectively. The biochemical disease‐free survival rates at 3 years for patients with pretreatment PSA less than 10 ng/mL, 10.01–20.0 ng/mL and more than 20.0 ng/mL were 94%, 75% and 35%, respectively (P 
ISSN:0919-8172
1442-2042
DOI:10.1111/j.1442-2042.2006.01272.x